Table 1.
Expression changes of estrogen-responsive genes in MCF-7 cells treated with E2 and SWT
| Fold change (treatment/control) | |||||
|---|---|---|---|---|---|
|
Affymetrix probe ID |
Gene symbol |
Description |
E2 |
SH |
SM |
|
Up-regulated genes | |||||
| 237460_x_at |
C14orf182 |
chromosome 14 open reading frame 182 |
13.77 |
6.29 |
1.18 |
| 228554_at |
PGR |
progesterone receptor |
12.10 |
2.83 |
1.72 |
| 205862_at |
GREB1 |
growth regulation by estrogen in breast cancer 1 |
10.87 |
5.08 |
2.37 |
| 206115_at |
EGR3 |
early growth response 3 |
10.69 |
10.70 |
1.65 |
| 235004_at |
RBM24 |
RNA binding motif protein 24 |
10.23 |
6.07 |
1.57 |
| 1557277_a_at |
|
|
8.71 |
2.08 |
1.32 |
| 231120_x_at |
PKIB |
protein kinase (cAMP-dependent, catalytic) inhibitor beta |
7.96 |
2.29 |
1.27 |
| 219525_at |
SLC47A1 |
solute carrier family 47, member 1 |
7.93 |
2.22 |
1.40 |
| 205440_s_at |
NPY1R |
neuropeptide Y receptor Y1 |
7.08 |
2.81 |
1.84 |
| 44790_s_at |
C13orf18 |
chromosome 13 open reading frame 18 |
7.08 |
2.97 |
2.59 |
| 213906_at |
MYBL1 |
v-myb myeloblastosis viral oncogene homolog (avian)-like 1 |
6.78 |
1.26 |
1.29 |
| 220038_at |
SGK3 |
serum/glucocorticoid regulated kinase family, member 3 |
6.63 |
1.79 |
1.51 |
| 222921_s_at |
HEY2 |
hairy/enhancer-of-split related with YRPW motif 2 |
6.11 |
2.88 |
1.59 |
| 228241_at |
AGR3 |
anterior gradient homolog 3 (Xenopus laevis) |
6.08 |
2.55 |
1.84 |
| 204798_at |
MYB |
v-myb myeloblastosis viral oncogene homolog (avian) |
5.96 |
2.37 |
1.92 |
| 227627_at |
SGK3 |
serum/glucocorticoid regulated kinase family, member 3 |
5.83 |
1.69 |
1.54 |
| 208018_s_at |
HCK |
hemopoietic cell kinase |
5.77 |
1.33 |
1.02 |
| 239777_at |
C14orf182 |
chromosome 14 open reading frame 182 |
5.63 |
3.29 |
1.27 |
| 207886_s_at |
CALCR |
calcitonin receptor |
5.38 |
2.59 |
1.86 |
| 232306_at |
CDH26 |
cadherin 26 |
5.37 |
3.51 |
1.94 |
| 219743_at |
HEY2 |
hairy/enhancer-of-split related with YRPW motif 2 |
5.30 |
1.83 |
1.37 |
| 208305_at |
PGR |
progesterone receptor |
5.22 |
1.69 |
1.10 |
| 223551_at |
PKIB |
protein kinase (cAMP-dependent, catalytic) inhibitor beta |
5.18 |
2.13 |
1.42 |
| 211421_s_at |
RET |
ret proto-oncogene |
4.98 |
1.54 |
1.19 |
| 205326_at |
RAMP3 |
receptor (G protein-coupled) activity modifying protein 3 |
4.67 |
2.35 |
1.87 |
| 244745_at |
RERG |
RAS-like, estrogen-regulated, growth inhibitor |
4.61 |
1.43 |
1.51 |
| 237334_at |
|
|
4.55 |
2.25 |
1.34 |
| 219702_at |
PLAC1 |
placenta-specific 1 |
4.45 |
2.02 |
1.09 |
| 223201_s_at |
TMEM164 |
transmembrane protein 164 |
4.44 |
1.68 |
1.23 |
| 219825_at |
CYP26B1 |
cytochrome P450, family 26, subfamily B, polypeptide 1 |
4.42 |
1.26 |
1.19 |
| 224428_s_at |
CDCA7 |
cell division cycle associated 7 |
4.39 |
1.11 |
1.45 |
| 209687_at |
CXCL12 |
chemokine (C-X-C motif) ligand 12 |
4.31 |
1.77 |
1.29 |
| 242064_at |
SDK2 |
sidekick homolog 2 (chicken) |
4.25 |
1.48 |
0.99 |
| 219985_at |
HS3ST3A1 |
heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 |
4.17 |
2.01 |
1.40 |
| 220486_x_at |
TMEM164 |
transmembrane protein 164 |
4.09 |
1.64 |
1.22 |
| 201739_at |
SGK1 |
serum/glucocorticoid regulated kinase 1 |
4.01 |
1.86 |
1.29 |
|
Down-regulated genes | |||||
| 242943_at |
ST8SIA4 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 |
0.31 |
0.40 |
0.85 |
| 202948_at |
IL1R1 |
interleukin 1 receptor, type I |
0.32 |
0.40 |
0.78 |
| 229354_at |
AHRR |
aryl-hydrocarbon receptor repressor |
0.33 |
0.83 |
0.80 |
| 230261_at |
ST8SIA4 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 |
0.36 |
0.41 |
0.88 |
| 230836_at |
ST8SIA4 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 |
0.37 |
0.35 |
0.88 |
| 228176_at |
EDG3 |
endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 |
0.38 |
0.67 |
0.95 |
| 205749_at |
CYP1A1 |
cytochrome P450, family 1, subfamily A, polypeptide 1 |
0.38 |
1.76 |
0.97 |
| 213413_at | BG434174 | STON1 | 0.39 | 0.27 | 0.63 |
Gene expression of MCF-7 cells after 6 hours of treatment with 0.1 μM E2 or SWT (2.56, 0.256 or 0.0256 mg/ml) was analyzed by microarrays. Listed are selected genes that showed strongest up-regulation or down-regulations induced by E2 by applying the cutoff of fold change > 4 for up-regulated genes, fold change < 0.4 for down-regulated genes, and false discovery rate (FDR) < 0.01. Expression values are shown by fold changes between treatment and control, i.e., expression values relative to untreated control cells for E2, SH and SM. Fold changes in bold: FDR < 0.01.